Peer-reviewed veterinary case report
Lorazepam lowers repeat urethral blockage in male cats after first
By Splittstoesser, Alexa et al.·Published in Journal of the American Veterinary Medical Association·2026·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Lorazepam reduces recurrence of urethral obstruction in male cats: a prospective, randomized, double-blinded, placebo-controlled study.
- Species:
- cat
Plain-English summary
A group of male cats with a first-time urethral obstruction (a blockage that makes it hard for them to urinate) was treated with lorazepam, a medication that helped prevent the blockage from happening again. In the study, none of the cats that received lorazepam had a recurrence of the obstruction, while 15% of those given a placebo did. Additionally, fewer cats on lorazepam showed signs of lower urinary tract issues after treatment. The medication was generally safe, though some cats experienced mild side effects like ataxia (loss of coordination) and increased appetite.
People also search for: male cat urethral obstruction treatment · lorazepam for cat urinary issues · cat urinary blockage prevention
Abstract
OBJECTIVE: To determine the efficacy of lorazepam in reducing the rate of recurrence in first-time feline urethral obstruction (UO) and frequency of lower urinary tract (LUT) signs following hospitalization, as well as adverse effects of the medication. METHODS: This was a prospective, randomized, double-blinded, placebo-controlled study of 80 client-owned male cats presenting to a university teaching hospital with UO between 2021 and 2025. Cats with urolithiasis or urinary tract infection were excluded. Cats received lorazepam or placebo for 1 month after hospitalization for UO. RESULTS: 41 cats received lorazepam and 39 cats received placebo. Sixty-four cats completed the study. Five of 64 cats experienced recurrence of UO, all receiving placebo. No cats receiving lorazepam had UO recurrence (0%; 95% CI, 0.0% to 10.9%) compared to the placebo group (15.7%; 95% CI, 5.2% to 33.7%); this was statistically significant. There was a statistically significant reduction in LUT signs for 2 of 33 cats during days 8 to 15 (95% CI, 0.7% to 20.2%) and 1 of 31 cats during days 16 to 30 (95% CI, 0.1% to 16.7%) for the lorazepam group. Ataxia was the only statistically significant side effect of lorazepam, occurring in 4 of 31 cats (13%); other reported effects included sedation, increased appetite, and vocalization. CONCLUSIONS: Lorazepam administration was associated with a reduction in the recurrence of UO in this study population, as well as reduced LUT signs compared to cats receiving placebo. Lorazepam administration was found to be safe. CLINICAL RELEVANCE: Lorazepam may be used safely in the reduction of both recurrent UO and LUT signs following alleviation of UO in male cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/42091068/